These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24980447)

  • 1. An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab.
    Sclafani F; Rimassa L; Colombo P; Destro A; Stinco S; Lutman FR; Carnaghi C; Beretta G; Zanello A; Roncalli M; Giordano L; Santoro A
    Int J Biol Markers; 2015 Feb; 30(1):e73-80. PubMed ID: 24980447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
    Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
    Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.
    Jordan F; Grundmann N; Schenkirsch G; Märkl B; Messmann H; Anthuber M; Schmid C; Trepel M
    Anticancer Res; 2018 Sep; 38(9):5539-5546. PubMed ID: 30194214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
    Maru DM; Kopetz S; Boonsirikamchai P; Agarwal A; Chun YS; Wang H; Abdalla EK; Kaur H; Charnsangavej C; Vauthey JN; Loyer EM
    Am J Surg Pathol; 2010 Sep; 34(9):1287-94. PubMed ID: 20697255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximab.
    Barbier A; Domont J; Magné N; Goldmard JL; Genestie C; Hannoun C; Vaillant JC; Bellanger A; Khayat D; Capron F; Spano JP
    Bull Cancer; 2010 Feb; 97(2):E9-E15. PubMed ID: 20085858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab.
    Garde-Noguera J; Gil-Raga M; Evgenyeva E; García JA; Llombart-Cussac A; Camps-Herrero C
    Clin Transl Oncol; 2016 Apr; 18(4):405-12. PubMed ID: 26307753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
    Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
    Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalent cross-relaxation rate imaging and diffusion weighted imaging for early prediction of response to bevacizumab-containing treatment in colorectal liver metastases-preliminary study.
    Matsushima S; Sato T; Nishiofuku H; Sato Y; Murata S; Kinosada Y; Era S; Inaba Y
    Clin Imaging; 2017; 41():1-6. PubMed ID: 27721090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy.
    Kara O; Duman BB; Kara B; Erdogan S; Parsak CK; Sakman G
    Asian Pac J Cancer Prev; 2012; 13(12):6397-401. PubMed ID: 23464465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab.
    Sasaki K; Margonis GA; Andreatos N; Wilson A; Weiss M; Wolfgang C; Sergentanis TN; Polychronidis G; He J; Pawlik TM
    Br J Surg; 2017 Jun; 104(7):926-935. PubMed ID: 28266705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
    Betge J; Barat A; Murphy V; Hielscher T; Van Grieken NC; Belle S; Zhan T; Härtel N; Kripp M; Bacon O; Cordes M; Kay EW; Verheul HM; Neerincx M; Hennessy B; Hofheinz RD; Gaiser T; Ylstra B; Prehn JH; Lambrechts D; Byrne AT; Ebert MP; Schulte N
    Digestion; 2016; 94(3):129-137. PubMed ID: 27756074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
    Umehara M; Umehara Y; Takahashi K; Murata A; Nishikawa S; Tokura T; Matsuzaka M; Tanaka R; Morita T
    Anticancer Res; 2016 Apr; 36(4):1949-54. PubMed ID: 27069185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.
    Guijarro-Muñoz I; Sánchez A; Martínez-Martínez E; García JM; Salas C; Provencio M; Alvarez-Vallina L; Sanz L
    Med Oncol; 2013; 30(2):572. PubMed ID: 23579861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.
    Wong HL; Lee B; Field K; Lomax A; Tacey M; Shapiro J; McKendrick J; Zimet A; Yip D; Nott L; Jennens R; Richardson G; Tie J; Kosmider S; Parente P; Lim L; Cooray P; Tran B; Desai J; Wong R; Gibbs P
    Clin Colorectal Cancer; 2016 Jun; 15(2):e9-e15. PubMed ID: 26968236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice.
    Razenberg LG; van Gestel YR; de Hingh IH; Loosveld OJ; Vreugdenhil G; Beerepoot LV; Creemers GJ; Lemmens VE
    BMC Cancer; 2016 Feb; 16():110. PubMed ID: 26882902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
    Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J
    Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.